Boliven Subscriptions: buy a subscription to Boliven and access advanced analytics and complete databases. Find out more »

What is the future of HFA pMDIs? A patent-based perspective

A significant number of patent expiries may create opportunities for pMDI innovation

Register or Login to view the shared list of associated patents that you can edit, share, export and analyse, or click here to see individual patents.


Read the full article at Inhalation magazine by clicking here direct to article


Summary

We have provided a supplement for the readers of the article that will allow you to:

  • Access a comprehensive list of the earliest patents in the HFA space and analytics related to these
  • Access the patents described in the article and other patent family members
  • Review patents that are likely to have expired, providing useful prior art for future developments (upcoming feature)

   Boliven6 Click to access lists and analytics


References

  • Protocole deMontreal relative a des substances qui appauvrissent la chouce d’ozone. Secretariat de l’ozone, Programme des Nations Unis pour l’environnement, 2000. ISBN 92-807-1888-6.
  • Radhakrishnan R, Mihalko PJ, Abra PM, inventor. Liposome Technology Inc., assignee. Method and apparatus for administering dehydrated liposomes by inhalation. US4895719; 1990.
  • Purewal TS, Greenleaf DJ, inventor. Riker Laboratories Incorporation, assignee. Medicinal aerosol formulations GB8828477; 1989.
  • Purewal TS, Greenleaf DJ, inventor. Riker Laboratories Inc, assignee. Medicinal aerosol formulations EP372777; filing 1989.
  • Steele G, Somani A, Lim JGP, inventor. Fisons Plc, assignee. Propellant compositions WO9111173A1; 1991.
  • Heiskel E, Schmieder W, inventor. Hoechst AG, assignee. Druckgaspackung und treibmittel fur Aerosole DE3905726A1; filing 1990.
  • Weil HH, Daab O, inventor. Boehringer Ingelheim, assignee. Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen DE4003272A1; filing 1990.
  • Weil HH, Daab O, inventor. Boehringer Ingelheim, assignee. Novel vehicle gas mixtures and their use in medical preparations WO9111495A1; filing 1990.



More high impact research from the CambridgeIP-Boliven team

  • Marketing your technology in the credit crunch

    Quentin Tannock and Miranda Weston-Smith, presented a tutorial on _marketing your technology in the credit crunch_ for representatives drawn from a select set of Technology Transfer Officers at four leading UK Universities.
  • IP & Climate Change: Crosslicensing, Patent Pools and Cooperative Standards

    IP & Climate Change: Crosslicensing, Patent Pools and Cooperative Standards

    It has become increasingly accepted that adoption and diffusion of technologies in developing countries crucially depends on creating a suitable enabling environment. Intellectual Property Rights (IPRs) play a key role in determining the channels and terms of such technology transfer.

    This paper takes a fact-based approach by exploring how in practice industries have dealt with IPRs.

  • Responsible Licensing for the Developing World

    _As a community of practitioners we can and should do more to provide innovative technology licensing solutions to our clients _ in both the developed and developing world_ As the market for low-carbon energy will increase exponentially, licensing solutions that may have been untenable in the past can become attractive_ This was the opening statement by CambridgeIP_s Ilian Iliev presenting to a group of licensing executives, IP managers and IP lawyers at London_s science museum on the topic of _Responsible Licensing for the Developing World_.

  • Harvard Business Review: 'Can Technology Really Save Us from Climate Change?'

    Harvard Business Review cites IP analysis in the Cleantech space done by CambridgeIP and Chatham House as a potential market tool to help direct the future clean-tech landscape more effectively. In addition, the article postulates on the potential influence of IP analysis to methodologically underpin a 'Moore's Law' for clean technology

  • Challenges & Opportunities in Licensing Renewable Technologies

    Challenges & Opportunities in Licensing Renewable  Technologies

    The article describes a new initiative dedicated to the licensing of renewables, framed within a discussion of the current issues and challenges of establishing and licensing renewable technologies.

  • Business Strategy: Putting IP at the Centre

    CambridgeIP contributed to the Innovation UK report on the topic of IP strategy. An effective IP strategy can become a centerpiece for a company's internationalisation strategy: providing it with leverage and protection across diverse markets, facilitating the generation of additional revenue through licensing activity, as well as currency for negotiating with large corporate partners.

  • Patents and Potency: The Stem Cell Patent Landscape

    Julian Hitchcock of Field Fisher Waterhouse LLP contributed this guest blog entry:
    The grant of a patent for induced pluripotent stem cells (iPSCs) in the United Kingdom in January and the notice issued by the US Patent and Trademark Office in February allowing claims under a US patent application entitled _Methods for Reprogramming Somatic Cells_ signal a significant new feature of the stem cell patent landscape. But don_t imagine that stem cell patents are about to become straightforward.

  • Harvard Business Review: 'Can Technology Really Save Us from Climate Change?'

    Harvard Business Review cites IP analysis in the Cleantech space done by CambridgeIP and Chatham House as a potential market tool to help direct the future clean-tech landscape more effectively. In addition, the article postulates on the potential influence of IP analysis to methodologically underpin a 'Moore's Law' for clean technology

  • Telehealth technology comes of age?

    Telehealth technology comes of age?

    CambridgeIP patent landscaping research finds that up to 89% of medical device patents involve wireless technology. The research, covering more than 26,000 telehealth related patents, has identified emerging patenting hotspots and changing market dynamics in telehealth technologies. Read CambridgeIP’s press release to find out more. You can also download the report. Here on Boliven.com, you can conduct your own analysis of the underlying patent datasets by visiting our blood glucose monitors Boliven Landscape.

  • Patent Citations, Geographic Spread and the role of China as a patent destination

    In CambridgeIP's report on AIM-listed patent-intensive companies they identified a subset of 68 AIM-listed companies that represent the bulk of patenting activity: out of more than 1,600 total companies. This is just one of the many interesting findings that can be found in the discussion of the report here.

  • Patents: When to sell & when to buy

    The opportunity exists in these pressing economic times for the canny investor to secure patents at a fraction of past prices. Moreover, there may be an increased opportunity to selectively acquire high value IP assets, rather than needing to acquire the IP bundled with other assets of less value to the investor.

  • Protecting and Growing Corporate Assets: A Strategic Case

    CambridgeIP's Ilian Iliev was a guest contributor to BusinessXL's special October edition focused on 'Why IP matters'. In his article Ilian argues that despite the downturn, a comprehensive and strategically integrated IP strategy remains key to long-term value creation.

  • Advanced Corporate Uses of Patent-based Intelligence

    CambridgeIP_s Ilian Iliev and Quentin Tannock led a workshop for the Licensing Executives Society for Britain and Ireland (LES-BI). The workshop_s focus was on Advanced Corporate Uses of Patent-based Intelligence_ in the context of an economic slowdown. The 30+ participants included IP managers from major corporations, University Technology Transfer Offices and SMEs; as well as IP service providers.

  • Technology Transfer Offices (TTOs) working with Corporate partners

    Quentin Tannock participated on a panel in the Tech Transfer Summit at EuroBio 2009 that considered the topic of TTOs working with Corporate partners. The audience was a mixture of major Pharma corporations, biotech companies and TTOs.

  • The Bulgarian Innovation System in a Time of Global Economic Crisis

    The Bulgarian Innovation System in a Time of Global Economic Crisis

    CambridgeIP was a contributor to the annual report Innovation.BG 2009, the leading innovation review for Bulgaria's economy, published by ARC Fund. CambridgeIP's analysis helped identify the historical IP outputs of Bulgaria and the Bulgarian Academy of Sciences.

Subscribe to Boliven
Join now for free »
Subscription options »


Authors

  • Ilian Iliev is CEO and co-founder, CambridgeIP Ltd.
  • Arthur Lallement is Senior Associate at CambridgeIP Ltd.
  • Daniela Traini is a Senior Lecturer, Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Australia
  • Philippe Rogueda is an Adjunct Senior Lecturer, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia


Cambridge IP Services

IP Landscape Report

CambridgeIP Landscape Reports for rapid, reliable and repeatable analysis of IP activity in complex technology spaces


Competitive Intelligence

CambridgeIP Competitive Intelligence to benchmark your company or your partners to key competitors, as well as identify prospective acquisitions, potential partners and licensing-out targets


Technology Market Review

CambridgeIP. Technology-Market Review reports provide a review of key technology development areas as they correspond to current and future market niche.


Open innovation and Technology Scouting

CambridgeIP's Open Innovation offering helps organisations benefit from external initiatives in their field of endeavour.